Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.
The AIkido Pharma Inc. platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University. AIkido Pharma also has an Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus, from the University of Maryland Baltimore.
Recently, Aikido Pharma secured an early investment in Convergent Therapeutics Inc, a startup pharmaceutical company focused on developing next generation radiopharmaceutical therapy for prostate cancer and other applications. Its proprietary technology involves peptide receptor radionuclide therapy (“PRRT”) developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.
The importance of this technology is rooted in its proprietary drug, CONV 01-α, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter. CONV 01-α was specifically designed to bind to the prostate-specific membrane antigen (“PSMA”).
For more information about Aikido Pharma Inc or Convergent Technologies get in touch with Aikido Pharma at 212-745-1373.